Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769490 | 0.86 | PTGDR2 (0.50) | PTGDR2ALOX5KDM4ENPC1PKM | |
| SCHEMBL28295525 | 0.80 | ALOX5 (0.60) | PTGDR2ALOX5PRMT1MAPTTP53 | |
| SCHEMBL3769955 | 0.78 | PTPN11 (0.58) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL3769265 | 0.78 | PTGDR2 (0.53) | PTGDR2ALOX5KDM4ENPC1RAB9A | |
| SCHEMBL13813824 | 0.73 | ALOX5 (0.52) | PTGDR2ALOX5KDM4ENPC1PKM | |
| SCHEMBL4803340 | 0.72 | ALOX5 (0.52) | PTGDR2ALOX5KDM4ENPC1ALDH1A1 | |
| SCHEMBL13801084 | 0.69 | KDM4E (0.61) | PTGDR2ALOX5KDM4ENPC1PKM | |
| SCHEMBL1672348 | 0.69 | FFAR1 (0.47) | KDM4ENPC1ALDH1A1MAPT | |
| SCHEMBL8005690 | 0.69 | PTGDR2 (0.68) | PTGDR2ALOX5KDM4ENPC1PKM | |
| SCHEMBL10993434 | 0.69 | PTGDR2 (0.59) | PTGDR2ALOX5MAPTTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934206-B1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| EP-1934206-B1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| US-7851493-B2 | Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-12-14 | — | — | US | disclosed |
| US-7851493-B2 | Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-12-14 | — | — | US | disclosed |
| US-7851493-B2 | Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-12-14 | — | — | US | disclosed |
| US-20090281084-A1 | PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
| US-20090281084-A1 | PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
| US-20090281084-A1 | PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
| US-20080287409-A1 | PHENYL AND PYRIDINYL-1,2,4-OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| US-20080287409-A1 | PHENYL AND PYRIDINYL-1,2,4-OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| US-20080287409-A1 | PHENYL AND PYRIDINYL-1,2,4-OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| EP-1934206-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039172-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039172-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287409-A1 | PHENYL AND PYRIDINYL-1,2,4-OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | PPARD, PPARA, PPARG | PTGDR2 276/4885ALOX5 925/4885KDM4E 2433/4885 |
| US-20090281084-A1 | PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | PPARD, PPARA, PPARG | PTGDR2 302/4885ALOX5 662/4885KDM4E 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.